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ABSTRACT 
The debate about whether misoprostol should be distributed to low resource 
communities to prevent post-partum haemorrhage (PPH), recognised as a 
major cause of maternal mortality, is deeply polarised. This is in spite of 
stakeholders having access to the same evidence about the risks and benefits 
of misoprostol. To understand the disagreement, we conducted a qualitative 
analysis of the values underpinning debates surrounding community 
distribution of misoprostol. We found that different moral priorities, epistemic 
values, and attitudes towards uncertainty were the main factors sustaining the 
debate. With this understanding, we present a model for ethical discourse that 
might overcome the current impasse. 
 
INTRODUCTION 
 
Almost all maternal deaths occur in the developing world1, of which the major 
causes are known to be post-partum haemorrhage (PPH), infection, eclampsia 
and unsafe abortion. The majority of these deaths (87%) occur in Sub-Saharan 
Africa and Southern Asia2. In these contexts, PPH is the leading cause of 
maternal mortality, being responsible for approximately one-third of all 
maternal deaths. In Latin America and the Caribbean, PPH is the second 
                                                          
1 N.M. Nour. An Introduction to Maternal Mortality. Reviews in Obstetrics and Gynecology 
2008; 1: 77-81; World Health Organisation. 2012. Maternal Mortality Fact Sheet No: 348. 
Available at: http://www.who.int/mediacentre/factsheets/fs348/en/index.html# [Accessed 18 
April 2013]. 
2
 United Nations. 2010. Millenium Development Goals Report 2010.  
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leading cause of maternal death after hypertensive disorders3. In contrast, 
maternal deaths in the developed world are most commonly due to ‘other 
direct causes’ (such as complications related to caesarean section and 
anaesthesia), hypertensive disorders, and embolism respectively4.  
PPH is treatable with the use of uterotonic drugs and other conservative 
interventions, with surgery being a last resort, but most women in Africa and 
Southern Asia usually give birth at home without skilled care5  and access to 
effective care within a reasonable time is not possible for many women in the 
developing world6. The problem, therefore, is not that PPH is untreatable, but 
that women cannot access the care they need. 
In response to the massive global inequity in maternal health, the United 
Nations set a target in 2000 to reduce maternal mortality by 75% between 
1990 and 2015 (Millennium Development Goal (MDG) 5). In the 20 years to 
2010, the rate of maternal mortality in developing countries has reduced by 
47%7, which although significant, falls far short of the United Nations’ targets. 
Many believe that the drug misoprostol is a key tool in the struggle to reduce 
maternal mortality in the developing world. Misoprostol is a prostaglandin E1 
analogue that was developed by Searle in 1973 and approved in the late 
1980’s for the treatment of gastric ulcers due to its ability to inhibit gastric acid 
secretions. It is also widely used ‘off-label’ for many other purposes including 
labour induction8 , abortion9, PPH10 , and as a general cervical ripening agent 
                                                          
3
 K.S. Khan, et al. WHO analysis of causes of maternal death: a systematic review. The Lancet 
2006; 367: 1066-1074. 
4 World Health Organisation. Maternal and Perinatel Health. Available at: 
http://www.who.int/reproductivehealth/topics/maternal_perinatal/epidemiology/en/ 
[Accessed 18 April 13].  
5
 United Nations, op. cit. note 2. 
6
 S. Naicker, et al. Shortage of Healthcare Workers in Developing Countries - Africa. Ethnicity 
and Disease 2009; 19: S1.60-64; UNFPA. 2003. Maternal Mortality Update 2002: A Focus on 
Emergency Obstetric Care.  
7 World Health Organisation. 2012. Trends in Maternal Mortality: 1990 to 2010. WHO, UNICEF, 
UNFPA and The World Bank estimates.  
8 Z. Alfirevic & A. Weeks. Oral misoprostol for induction of labour. Cochrane Database of 
Systematic Reviews 2010; G.J. Hofmeyr, A.M. Gulmezoglu & C. Pileggi. Vaginal misoprostol for 
cervical ripening and induction of labour. Cochrane Database of Systematic Reviews 2010; E. 
Krause, et al. Off-label use of misoprostol for labor induction: a nation-wide survey in 
Switzerland. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011; 
159: 324-328. 
9 H. von Hertzen, et al. Comparison of vaginal and sublingual misoprostol for second trimester 
abortion: randomized controlled equivalence trial. Human Reproduction 2009; 34: 106-112; 
J. Chai, et al. A randomized trial to compare two dosing intervals of misoprostol following 
mifepristone administration in second trimester medical abortion. Human Reproduction 2009; 
24: 320-324. 
10 G.J. Hofmeyr, et al. Misoprostol to prevent and treat postpartum haemorrhage: a 
systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World 
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to ease other obstetric and gynaecological interventions11. Importantly, 
misoprostol is cheap, stable at ambient temperature and therefore requires no 
special storage, and is easy to administer because it comes in an oral tablet 
form. In 2006 the International Federation of Gynecology and Obstetrics 
(FIGO) and the International Confederation of Midwives argued that 
distributing misoprostol to communities may be the only realistic way to 
manage PPH in low-resource communities12. 
While convincing evidence exists that misoprostol is efficacious in 
management of PPH13 , it is less clear how to deliver the drug safely to those 
who need it most. In particular, very little is known about the benefits and 
risks associated with community distribution of misoprostol in low resource 
settings. In 2012 both a Cochrane review and systematic review published by 
Chu and colleagues reported that there is no definitive evidence to support 
distribution of misoprostol in low resource settings14. The Cochrane review 
identified only three relevant studies of which none met the inclusion criteria, 
while Chu’s review identified 176 studies of which only 6 met the inclusion 
criteria.   
In the face of this evidentiary uncertainty, people have expressed widely 
divergent views as to how widely, if at all, misoprostol should be distributed in 
the developing world. Some have argued that community distribution of 
misoprostol is a poor option for addressing PPH in low resource communities, 
while others have strongly advocated for its use15. WHO and FIGO have been 
circumspect in their recommendations regarding community distribution, 
                                                                                                                                                          
Health Organ 2009; 87: 666-677; J. Blum, et al. Treatment of post-partum haemorrhage with 
sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-
blind, randomised, non-inferiority trial. The Lancet 2010; 375: 217-223; B. Winikoff, et al. 
Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in 
women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority 
trial. The Lancet 2010; 375: 210-216. 
11 W.L. Cowman, et al. Vaginal misoprostol aids in difficult intrauterine contraceptive removal: 
a report of three cases. Contraception 2012; 83: 281-284; K. Cepni, et al. Randomised trial of 
oral misoprostol treatment for cervical ripening before tandem application in cervix cancer. 
International Journal of Radition Oncology, Biology and Physics 2011; 81: 778-781; 
N.P. Polyzos, et al. Misoprostol prior to hysteroscopy in premenopausal and postmenopausal 
women. A systematic review and meta-analysis. Human Reproduction Update 2012; 18: 393-404. 
12
 M. Potts, N. Prata & N.N. Sahin-Hodoglugil. Maternal mortality: one death every 7 min. The 
Lancet 2010; 375: 1762-1763. 
13
 Winikoff, et al. op. cit. note 10. 
14 O.T. Oladapo, et al. Advance misoprostol distribution for preventing and treating 
postpartum haemorrhage. Cochrane Database of Systematic Reviews 2012; C.S. Chu, P. 
Brhlikova & A.M. Pollock. Rethinking WHO guidance: a review of evidence for misoprostol use 
in the prevention of postpartum haemorrhage. Journal of the Royal Society of Medicine 2012; 
105: 336-347. 
15 C. Ronsmans & W. Huang. Community based interventions to reduce maternal mortality. 
The Lancet 2010; 375: 457; M. Potts, et al. Empowering women to control post-partum 
haemorrhage. The Lancet 2010; 375: 459-450. 
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settling to support its use in circumstances where alternative 
pharmacotherapy is not available16. WHO in particular is concerned about 
lingering safety concerns and uncertainties associated with widespread 
community distribution of misoprostol17 , and has recommended that  
rigorous research is needed18. 
With the inclusion of misoprostol in the 2011 WHO Essential Medicines List for 
the ‘prevention of postpartum haemorrhage where oxytocin is not available or 
cannot be safely used’ a consensus of sorts seemed to have been reached 
between stakeholders. However, as of March 2013, two contradictory 
applications to review the approved indications of misoprostol in the Essential 
Medicines List had been submitted19. One sought to expand misoprostol’s use 
in management of PPH, and another sought to delete misoprostol for 
prevention of PPH under any circumstances.  
This raises the question: why do some people support community distribution 
of misoprostol, while others are opposed to this course of action, whether 
absolutely or conditionally, when both groups face the same level of 
evidentiary uncertainty? It seems that, as might be expected in any complex 
policy arena, deeply held convictions of governments, researchers, the medical 
establishment, and not-for-profits, in addition to evidence, are contributing to, 
and even dictating, the terms of the debate.  
In this article we attempt to deconstruct the debate around community 
distribution of misoprostol for PPH in the developing world, and characterise 
its main conceptual features and tensions. We do not seek to provide a 
normative analysis as to whether or not the evidence supports the case for 
misoprostol’s distribution. Nor do we try to provide a historical analysis of how 
attitudes have adapted as the evidence base has evolved. Rather, we seek to 
make visible the values underpinning stakeholders’ published opinions, and to 
demonstrate that these can be just as important as (and sometimes more 
important than) the evidence with which they are presented.  
 
METHOD 
                                                          
16 A.M. Gulmezoglu, et al. Misoprostol use in the community to reduce maternal deaths. The 
Lancet 2010; 376: 955; FIGO. 2012. Misoprostol for PPH in low resource settings initiative. 
Available at: http://www.figo.org/projects/figo-misoprostol-post-partum-haemorrhage-low-
resource-settings-initiative [Accessed 18 April 2013]. 
17
 Ibid. 
18
 World Health Organisation. 2010. Clarifying WHO position on misoprostol use in the 
community to reduce maternal death. Available at: 
http://whqlibdoc.who.int/hq/2010/WHO_RHR_10.11_eng.pdf [Accessed 18 April 2012]. 
19 World Health Organisation. 2013. Essential Medicines Selection. Available at: 
http://www.who.int/selection_medicines/committees/expert/19/applications/en/ [Accessed 
18 April 2013]. 
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We performed a qualitative analysis of the debate surrounding the community 
distribution of misoprostol for PPH in low resource settings, as evident in 
opinion pieces (editorials, commentaries and letters) in medical journals, using 
concepts derived empirically from the broader debate around the off-label use 
of misoprostol in maternal health.  
In this study health and medical journals were the main source of evidence. 
Our sampling frame was kept as general as possible to capture a broad 
understanding of the issues surrounding misoprostol for maternal health. 
Since our research was concerned with the subjective views of stakeholders 
rather than the evidence for or against misoprostol’s use for various 
indications, we searched Google Scholar for editorials, comments, 
correspondences and letters in journal articles using the search term 
‘misoprostol’. Although no timeline was pre-selected, it emerged that the 
most appropriate starting year for the analysis was 2000 as it coincided with 
the establishment of the Millennium Development Goals, which are of 
particular importance to the maternal health debate, and therefore the 
misoprostol debate. The final month for collecting data coincided with the 
beginning of our analysis in June 2012.  
In keeping with the principles of qualitative research, we began to analyse the 
materials immediately using Morse’s outline of the cognitive basis of 
qualitative research20, and Charmaz’s outline of data analysis in grounded 
theory21. We entered all articles into an Excel spreadsheet paragraph by 
paragraph and began to identify themes. Articles were collected until it was 
clear that thematic saturation was reached – that is, until we reached a point 
at which no new themes were emerging in our analysis. To ensure that no 
critical issues were overlooked we searched the Lancet, British Medical 
Journal, New England Journal of Medicine, the Journal of the American 
Medical Association, PLOS Medicine, and the Annals of Internal Medicine using 
their advanced search utilities using the search term ‘misoprostol’ and filtering 
by editorials, correspondences, comments, or letters. In total approximately 
50 articles were reviewed as part of this research.  
Themes were collated into the following categories by the first author: the 
nature, purpose and context of evidence; safety and clinical uncertainty; 
ethical concerns; regulatory concerns; and health service delivery.  With these 
categories in mind, several cycles of immersion in the data and crystallisation 
of insights were undertaken to identify the fundamental differences in values 
                                                          
20 J.M. Morse. 1994. 'Emerging from the data': The cognitive processes of analysis in 
qualitative inquiry. In Critical issues in qualitative research methods. J.M. Morse, ed. 
ThousandOaks: Sage. 
21 K. Charmaz. 2006. Constructing grounded theory: a practical guide through 
qualitative analysis. London: Sage. 
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essential to the apparent disagreements22. A theoretical framework was 
developed that the authors agreed had explanatory power with regards to 
understanding the nature of the debate. The theoretical framework was then 
applied to the more focused debate around community distribution of 
misoprostol for PPH in low-resource settings.  
 
RESULTS 
 
Arguments against misoprostol distribution 
Those against community distribution of misoprostol for PPH in the developing 
world were concerned primarily with the fact that it has been associated with 
adverse side effects, some serious, and that these complications may increase 
in number or become even more serious if misoprostol were distributed 
widely in low-resource settings. This was seen to be partly because adequate 
monitoring and controls in these settings are unavailable, therefore increasing 
the likelihood of harm.  
Others focused their attention on the fact that the evidence base for 
community distribution of misoprostol continues to be disputed, or is weak. 
When Pagel and colleagues developed a model to assess the effectiveness of 
potential strategies to improve maternal health, for example, they were 
criticised by some for using unjustified estimates of misoprostol’s 
effectiveness in reducing mortality from PPH. It was argued that a Cochrane 
Review published in 2007 had indicated that there was no evidence of 
misoprostol’s effectiveness on maternal mortality reduction and ‘substantial 
heterogeneity of effect on severe postpartum haemorrhage’23. While WHO 
included misoprostol in the Essential Medicines List for PPH, they have never 
recommended its distribution, stating that: 
 ‘…WHO does not recommend such practices [community distribution 
of misoprostol] with unknown benefits and harms.’24 
Contributing to the uncertainty of evidence claims was the argument that 
blood loss is notoriously difficult to measure accurately and that this has 
compromised comparative studies25. Some, therefore, have argued that the 
only reliable way to generate data about maternal mortality from PPH would 
                                                          
22 S.L. Schensul, J.J. Schensul & M.D. LeCompte. 1999. Essential Ethnographic Methods. 
Oxford: Altamira Press. 
23 Ronsmans & Huang , op. cit. note 15. 
24
 Gulmezoglu, et al. op. cit. note 16, p. 955. 
25
 R. Khan & S. Sharma. Use of misoprostol in third stage of labour. The Lancet 2002; 359: 708-709. 
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be direct observation of deaths, which would require large and complex 
trials26.  
The fact that misoprostol has not been subject to regulatory approval for 
management of PPH (that is, is used off-label for this indication) was seen to 
add further uncertainty because it meant that there was insufficient official 
guidance on the most effective and safest dosage regimens27.  
Those against community distribution of misoprostol for PPH in low resource 
settings therefore preferred to wait for certainty, on the basis of further high-
grade evidence, to ensure that the intervention was safe before promoting 
widespread distribution of misoprostol. 
 
Arguments in favour of misoprostol distribution 
Those in favour of community distribution of misoprostol for PPH in the 
developing world were primarily motivated by what they saw as the 
unconscionable inequity in maternal mortality. PPH was framed as a ‘scourge’ 
that needed to be eliminated, and the women most at risk were seen as 
vulnerable and powerless, requiring protection28.  
Advocates of community distribution of misoprostol did not deny the fact that 
gaps in the evidence base existed, but they claimed that the use of lower 
standards of evidence was legitimate because it would be difficult, if not 
impossible, to generate high-grade evidence for logistical, ethical and financial 
reasons29. Great need, combined with a low prospect of generating high-grade 
evidence, was seen as an adequate (if not ideal) basis for action30. 
Some advocates of community distribution of misoprostol also sought to 
strengthen the case for using weaker evidence by challenging the sacrosanct 
nature of high-grade evidence. They claimed that even the best research is 
only informative about the settings in which it is conducted. For instance Potts 
and colleagues described how two studies examining the comparative 
effectiveness of misoprostol and oxytocin, one conducted in well-resourced 
hospitals and the other in Egyptian hospitals, reported contradictory results31. 
By suggesting that even high-grade evidence would not resolve the dispute 
                                                          
26
 A. Weeks. Oral misoprostol for postpartum haemorrhage. The Lancet 2006; 368: 2123. 
27 Blum, et al. op. cit. note 10; N. Deole & A. Weeks. Knowledge of correct dosages of 
misoprostol in reproductive health. International Journal of Gynecology and Obstetrics 2010; 
109: 71-77. 
28 M. Potts, et al. op. cit. note 15; P.D. Darney. Misoprostol: a book to safe motherhood...or 
not? The Lancet 2001; 358: 682. 
29
 M. Potts, et al. op. cit. note 12. 
30 M. Potts, N. Prata & N.N. Sahin-Hodoglugil. Misoprostol use in the community to reduce 
maternal death. The Lancet 2010; 376: 955-956. 
31
 M. Potts, et al. op. cit. note 12. 
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about using misoprostol for management of PPH, the use of other forms of 
justification could be more easily legitimised.  
Advocates of misoprostol distribution also questioned claims about the side 
effects of misoprostol. For instance, in response to safety concerns highlighted 
by critics, Potts and colleagues argued that since its introduction, misoprostol 
has been used by millions of people for many indications, in high doses and for 
extended periods of time, including self-administration of misoprostol in the 
developing world. They therefore asked: 
‘Are deaths occurring and going unregistered, or is misoprostol not 
only a highly effective drug but also a remarkably safe one?’32 
Whatever risks did remain were seen by proponents to be insignificant ‘in 
comparison to the very real danger of post-partum haemorrhage after home 
births where skilled attention is inaccessible’33.   
 
DISCUSSION 
 
Conflicting ‘prudences’ 
In deconstructing the values underpinning the debate about community 
distribution of misoprostol it became evident that there was one key question 
implicitly shaping the arguments of both ‘sides’: at what point is it ethical to 
take action? In other words, the co-existence of scientific, clinical, and ethical 
uncertainty, combined with conflicting moral priorities, have created a tension 
that has split the professional community between those who maintain a 
‘conservative’ risk-averse position and those who seek a more ‘progressive’ 
solution to the misoprostol dilemma.  
More specifically, these two groups differ with respect to 1) their tendency to 
focus on harm, or on benefit and justice, 2) their willingness to act in the face 
of uncertainty, and 3) their views about the need for ‘strong’ scientific 
evidence.  
Those against community distribution of misoprostol in low resource settings 
were ‘conservative’ in that they were concerned about the potential for 
causing harm, found the degree of scientific and clinical uncertainty 
unacceptable, and were the strongest supporters of the need for generating 
robust scientific evidence before acting. On the other hand, proponents of 
distributing misoprostol wanted to challenge the status-quo. They focused 
more on the potential benefits of distributing misoprostol, and were willing to 
act on higher levels of uncertainty and accept lower standards of evidence to 
support their case.  In other words there was a strong correlation between 
                                                          
32
 Ibid: 1763 
33
 M. Potts, et al. op. cit. note 15. 
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epistemic and moral values. Those who emphasised the ethical principle of 
non-maleficence most strongly were most strict about evidence requirements 
and least tolerant of uncertainty, whereas those who emphasised beneficence 
tended to be more lenient about epistemic standards. We defined these two 
positions as variants of ‘prudence’—precautionary prudence and active 
prudence respectively (Figure 1). 
Figure 1: Mapping of prudential commitments observed in the misoprostol 
debate in terms of the correlation between moral priorities and epistemic 
standards 
 
 
 
 
 
 
 
 
 
 
As well as being implicit in the pro- and anti-distribution arguments, these two 
versions of prudence can be seen explicitly in the discourse of prominent 
spokespeople. In a commentary about the difficulties associated with 
generating definitive evidence about harms, Luis Cuervo, former Clinical Editor 
of BMJ, and Mike Clarke, former Co-Chair of the Cochrane Collaboration 
Steering Group (the group responsible for overseeing the development and 
implementation of policy affecting the Cochrane Collaboration) expressed a 
position consistent with active prudence in reference to misoprostol: 
‘When insufficient data are available to ascertain the size of the 
problem for an intervention and for any alternatives, people may end 
up worse off. They might be deprived of an intervention that is on 
balance more beneficial than harmful ...’34 
On the other hand, WHO, in defence of their conservative position on 
misoprostol, drew upon a statement by Sir Iain Chalmers, one of the founders 
of the Cochrane collaboration, which expresses the precautionary prudential 
principle: 
                                                          
34 L.G. Cuervo & M. Clarke. Balancing benefits and harms in health care: we need to get better 
evidence about harms. British Medical Journal 2003; 327: 65-66: 66. 
10 | P a g e  
 
‘Because professionals sometimes do more harm than good when they 
intervene in the lives of other people, their policies and practices 
should be informed by rigorous, transparent, up-to-date evaluations.’35 
WHO interpreted ‘rigorous, transparent, up-to-date evaluations’ to mean 
randomised controlled trials, systematic reviews, and evidence based clinical 
and public health practice guidelines. 
Our notion of ‘prudence’ is consistent with that of Aristotle, for whom 
‘prudence’ involved the application of intuitive reason to scientific knowledge. 
Prudence therefore has a subjective aspect that makes it difficult, if not 
impossible, to quantify36. Aristotle did not describe how to define a prudent 
decision, but instead argued that prudence was best manifested by ‘virtuous’ 
people who possessed the capacity to reason in particular ways. For the 
purposes of our paper we understand prudence as the conflation of 
knowledge and values in the selection of a preferred option, and we assume 
that conflicting ‘prudences’ will inevitably be manifest when stakeholders 
committed to different value systems participate in a debate.  
It is not surprising that different stakeholders should take up different versions 
of prudence in the misoprostol debate. Regulators and intergovernmental 
organisations have good reason to be risk-averse due to their responsibility for 
large numbers of people and the potential far reaching impacts that their 
decisions can have. Professional bodies and individual clinicians are 
understandably driven by their immediate desire to help patients, whether by 
avoiding harm or maximising benefits. And the pharmaceutical industry’s 
views will necessarily be shaped, at least in part, by commercial 
considerations. These political, clinical and commercial commitments lead, in 
turn, to differing conceptions of prudence in the face of a particular body of 
evidence (or lack thereof). 
 
Practical implications 
This in turn raises the question of how we can move past intractable moral 
and political disputes about community distribution of misoprostol. We 
believe that it is possible for those engaged in these debates to make progress, 
and we will explain this assertion with reference to Gallie’s notion of 
‘essentially contested concepts’, and theories of public discourse. 
                                                          
35
 World Health Organisation, op. cit. note 18, p. 2. 
36 Aristotle. 1980. Book VI. In Nicomachean Ethics. Oxford University Press. 
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According to Gallie37, a philosopher who explored the nature of disputes, 
apparently intractable disagreements of the kind we have presented here are 
a natural consequence of ‘essentially contested concepts’ embedded in the 
debate. Gallie outlined several conditions that might suggest that a concept is 
essentially contested (of which we will describe the two most relevant for our 
purposes). First, the concept must be appraisive, in the sense that it assigns a 
value to some outcome that is not measurable in any objective sense. For 
instance, the concept ‘beneficial’ can be applied by many different people in 
different ways. To label something beneficial is to give it a value, but this 
doesn’t mean that all will agree that it is. In the misoprostol debate, control of 
PPH is seen as benefit enough by one side, but not by the other, which sees 
evidence of reduced mortality as the only acceptable indication of benefit. 
Second, an essentially contested concept must be complex, in the sense that 
its meaning is derived from other concepts, while at the same time not being 
reducible to them. Therefore contesting parties can construct different 
opinions based on the relative value they give to the sub-concepts. For 
instance, a ‘good’ health policy intervention may depend on differing 
judgements about cost-effectiveness, sustainability of the intervention, and 
the most important clinical or public health end-point. In the case of reducing 
maternal mortality, some see community distribution of misoprostol as an 
excessively simplistic and reductionist option, arguing that it is a ‘seductively 
cheap’ short-term solution, and that the real need is for long-term 
commitment to health facility strengthening38. Importantly, Gallie described 
how both parties in a debate containing an essentially contested concept may 
have perfectly legitimate and rational arguments to support their differing 
positions, yet no objective principle can be found to determine which position 
is better.   
Prudence fulfils the criteria for being an essentially contested concept. It is a 
qualitative concept open to different interpretations, as we have 
demonstrated, and is also complex, requiring ‘virtuous’ judgements about (at 
the very least) morality, epistemic standards, and uncertainty.  
The implication of this is that if prudence is accepted as essentially contested, 
then there will be no decisive ‘technical-scientific’ solution to the misoprostol 
debate. Indeed it seems the issue at hand is so complex and so ridden with 
value judgements that further research, even though important, may never 
lead to universal agreement about the best course of action. With this in mind, 
it is clear that new ways of thinking are needed39.  
                                                          
37 W.B. Gallie. Essentially Contested Concepts. Preceedings of the Aristotelian Society, New 
Series 1956; 56: 167-198. 
38
 Ronsmans & Huang, op. cit. note 15. 
39 K. Kastenhofer. Risk assessment of emerging technologies and post-normal science. Science, 
Technology & Human Values 2011; 36: 307-333.  
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We believe that in order to move forward with the misoprostol debate, it 
needs to be recognised that the debate is an example of a ‘public discourse’. 
Public discourse is essential to democracy as it represents a form of speech 
that helps to form public opinion, and allows society to ponder what it 
believes and thinks40. However, public discourses are not free from the 
expression of power in various guises, with those who have more power 
influencing the discourse in their favour. Habermas believed that the liberal 
ideology had failed as it allowed for the concentration of power in private 
hands, such that ‘society... [had] to relinquish even the flimsiest pretence of 
being a sphere in which the influence of power was suspended’41. More 
recently, the late health economist Gavin Mooney commented on the 
influence of the neoliberal ideology in perpetrating disparities of power, 
resulting in private and institutional interests taking priority over 
‘communitarian claims’, and ultimately leading to poorer health outcomes42.   
Habermas suggested that the way to diffuse disparities in power was through 
‘discourse ethics’43. This approach was based on the premise that moral norms 
can only claim validity if they meet with the consent of all parties that would 
be affected by its introduction. He argued for a structured discourse where 
agreement must be reached through moral argumentation governed by 
rationality and due consideration of the concerns of all participants in the 
discourse. Mooney, on the other hand, believed that the power for allocating 
health care resources should rest firmly with communities, and suggested that 
the best way of identifying their preferences was to use ‘citizens’ juries’ 
comprised of a representative cross-section of the community. Experts provide 
relevant information to the jury, and the jury has the opportunity to question 
the experts, after which the jury deliberates and decides on their preferred 
course of action.  
Within the context of the misoprostol debate, we disagree with Habermas’ 
premise that all parties affected by a decision must consent to it in order for it 
to be morally valid, because not all parties are equally affected by a decision. It 
is also not clear how one would go about defining all of those ‘affected’ and 
how one could ever reach a situation of universal consent. Instead we believe 
that an approach similar to Mooney’s could help achieve local resolution of 
the misoprostol debate. While people in low resource settings might not be 
familiar with the latest scientific evidence about misoprostol, they will have a 
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particular appetite for uncertainty, a particular set of desires and fears, and a 
particular willingness to trade off risks for benefits. By synthesising the 
technical knowledge provided by experts and the views of communities about 
their moral priorities, attitudes towards uncertainty, and beliefs about the 
value of different types of evidence, the essentially contested concepts at the 
heart of the misoprostol debate might be revised. Importantly, given the 
inherently contested nature of debates such as the one we have presented, 
communities would need to be given the opportunity to revise their position 
as the consequences of their decision becomes apparent, and as significant 
new information becomes available.  
Of course, it must be kept in mind that this method is an analogy for the jury 
system in Western legal practice. Other practical analogies may be more 
appropriate to the decision-making frameworks that exist in different cultures. 
We therefore propose that as far as possible communities should be engaged 
through social processes already embedded in their culture.  
Importantly, if this approach was taken, stakeholders such as WHO would 
need to also accept that not all communities will share the same epistemic and 
moral standards, and therefore that seeking a ‘global’ solution may be 
counterproductive.  
Although the discourse ethic described in this paper would be difficult to 
govern and implement, we believe it is the necessary price for making 
decisions under uncertainty and sustained disagreement. It is difficult to see 
how under such circumstances any other approach could ensure that 
community values are not sidelined by power and global thinking. 
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